Multiple Myeloma KarMMA Trial Methodology: Larry Anderson, MD

Video

The associate professor from Harold C. Simmons Comprehensive Cancer Center discussed the methodology of the phase 2 KarMMa trial.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Larry Anderson, MD, PhD, associate professor, Department of Internal Medicine, Division of Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, about the methods utilized in the phase 2 KarMMa trial (NCT03361748) in multiple myeloma (MM).

The KarMMa trial investigated the efficacy and safety of idecabtagene vicleucel (ide-cel; Abecma) in patients with relapsed/refractory MM. Updated data was presented at the 2021 International Myeloma Workshop.

Prior to ide-cel administration, peripheral blood autologous T cells are taken via leukapheresis from a patient and modified with a viral vector to express a CAR T-cell receptor that recognizes BCMA, a plasma cell–specific surface protein on myeloma cells that is not expressed on other normal tissue, Anderson explains. In the KarMMa trial, 128 patients with relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy were treated with ide-cel across a target dose range of 150 x 106 to 450 x 106 CAR T cells, Anderson adds. Patients had received a median of 6 prior lines of therapy, with a range from 3 to 16, Anderson concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.